[Defective iron metabolism in genetic hemochromatosis. The mechanisms remain unknown in spite of genetic advances].
Genetic haemochromatosis (GH) is one of the most common hereditary diseases, with a prevalence of 1-5/1000 in the Western world. In 90 per cent of cases a mutation is found in an MHC-class-like gene designated HFE, involving a substitution at position 282 of the HFE protein and resulting in defective binding of beta(2)-microglobulin. Animals with beta(2)-microglobulin deficiency develop iron overload, indicating this protein to be involved in the regulation of iron metabolism. Hepatic iron overload results in increased production of oxygen free radicals and peroxidation of membrane lipids, thus causing damage to lysosomes, mitochondria and the endoplasmic reticulum. These cellular events may progress to cell death, fibrogenesis, and the development of liver cirrhosis which is associated with a 200-fold increase in risk of hepatocellular carcinoma. In addition to the risk of diabetes, arthralgia, cardiac arrhythmia, pituitary insufficiency and hypogonadism, iron excess is also associated with aggravation of the cytotoxic effects exerted on hepatocytes by other agents such as alcohol or hepatotrophic viruses. The treatment of iron overload in GH consists of weekly venesection until the serum ferritin level is normalized, followed by maintenance therapy. Survival rates are normal if the disease is detected and treated before complications have developed.
Stål
P
P
Gastroenterologiskt Centrum, Huddinge Sjukhus.
Hagen
K
K
Hultcrantz
R
R
D003937:Diagnosis, Differential; D005260:Female; D005805:Genes, MHC Class I; D006432:Hemochromatosis / Q000150:complications / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007501:Iron / Q000378:metabolism; D019190:Iron Overload; D008297:Male; D017354:Point Mutation; D011379:Prognosis; D012333:RNA, Messenger; D012307:Risk Factors
D012333:RNA, Messenger; D007501:Iron